ABBOTT LABORATORIES (NY:ABT)

View All ReportsStreetInsider.com Reports on ABT

Nov 20, 2009 11:43 AM Abbott (ABT) sues Teva (TEVA) over its drug for kidney patients, Zemplar

Nov 17, 2009 03:07 PM Hilliard Lyons Downgrades Abbott Labs (ABT) to Long-Term Buy

Nov 17, 2009 08:13 AM Morgan Joseph Initiates Coverage on Boston Scientific (BSX) with a Hold; Shares Fully Valued

Nov 16, 2009 03:04 PM Abbott (ABT) Announced 3-Year Data from First Phase of ABSORB Clinical Trial

Nov 12, 2009 11:14 AM Goldman Sachs Highlighted Some Great Dividend Plays: ABT, VZ, PM, FTR, MO, more...

View All Press ReleasesCompany Press Releases on ABT

Nov 19, 2009 02:00PM The Deal Names Abbott Top Dealmaker for Second Consecutive Year

Nov 17, 2009 08:30AM Abbott to Develop New Heart Failure Test on ARCHITECT(R) Immunochemistry Diagnostics Platform

Nov 16, 2009 06:01PM 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer

Nov 16, 2009 03:00PM Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial

Nov 16, 2009 07:00AM Watson Names Robert A. Stewart Senior Vice President, Global Operations

StreetInsider Reports on ABT by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on ABT

Nov 18, 2009 12:39 PM Winning Investment Strategy: Focus on Value-Based Dividend Growth

Nov 17, 2009 08:41 AM Will Questions over Cholestorol Drug Zetia Create a Major Setback for Merck?

Nov 16, 2009 12:26 PM Direction of Cholesterol Debate Could Benefit Abbott Labs

Nov 16, 2009 10:41 AM Cholesterol Drug Trials: A Victory for Abbott Means a Loss for Merck

Nov 16, 2009 07:19 AM Wall Street Breakfast: Must-Know News

View All FilingsSEC Filings on ABT

Nov 20, 2009 07:48PM Form 4 ABBOTT LABORATORIES For: Oct 01 Filed by: WHITE MILES D

Nov 19, 2009 06:38PM Form 4 ABBOTT LABORATORIES For: Nov 18 Filed by: Fussell Stephen R

Nov 13, 2009 06:21PM Form 4 ABBOTT LABORATORIES For: Nov 12 Filed by: Bohuon Olivier

Nov 13, 2009 06:07PM Form 4 ABBOTT LABORATORIES For: Oct 22 Filed by: Landgraf John C

Nov 13, 2009 06:06PM Form 4 ABBOTT LABORATORIES For: Nov 11 Filed by: FREYMAN THOMAS C

Comments on recent ABT articles

gary goldsmith
on Nov 12, 2009
at 08:02 PM dividend on At&T I think that there is an error with the dividend calculation for T. It is around 6.3%, not 3.2%
Article: Goldman Sachs Highlighted Some Great Dividend Plays: ABT, VZ, PM, FTR, MO, more...

curious Bug
on Sep 28, 2009
at 10:37 PM M&A jargon - accretive Sorry to ask a fundamental question - can someone explain in plain English what 'accretive' means and it's implications - as far as timelines on profitability of merger? Tx
Article: Abbott (ABT) Acquires Solvay Pharmaceuticals Business for $6.6 Billion

Brandon
on Sep 7, 2009
at 04:55 PM ABT Continue to be LONG ABT.
Article: Notable Mergers and Acquisitions of the Day 9/3: SEPR, ABT, JAVA/ORCL, TMO

tom
on Aug 18, 2008
at 03:43 PM crocs and Bill gates Bill must have taken a bath on the Crocs purchase. Was reported that in June he reported that they raised their stake. Looks loike they lost $4 million at least on that one. Good job.
Article: Gates' The Bill and Melinda Gates Foundation Shows New Positions in Crocs (CROX), Dick's (DKS) and Raised Stakes in McDonald's (MCD), FedEx (FDX) and AIG (AIG)

Kevin Ott
on Jul 2, 2008
at 05:46 PM Congrats to BSX This is great news for the DES market. BSX will be the first and only for the seeable future to have two distinct platforms to finally give doctors a choice. After much debate for several years, finally a company can offer a choice without having to pressure physicians to only their product. Even though ABT also has the product under the name Xience, they still do not have the ability to offer choice. Both products have demonstrated effectiveness and BSX has a real stake in the landscape.
Article: Boston Scientific (BSX) Receives FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System

Comments on ABT

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?